Get the Stockscreener App
2.10
2.78%
-0.06
After Hours:
2.09
-0.01
-0.48%
Proqr Therapeutics N V stock is traded at $2.10, with a volume of 657.15K.
It is down -2.78% in the last 24 hours and down -0.94% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.16
Open:
$2.12
24h Volume:
657.15K
Relative Volume:
1.23
Market Cap:
$221.22M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-5.5438
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
+3.96%
1M Performance:
-0.94%
6M Performance:
-4.55%
1Y Performance:
-19.85%
1-Day Range:
$2.07
$2.1927
1-Week Range:
$1.92
$2.275
52-Week Range:
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.10 | 227.55M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Why ProQR Therapeutics N.V. (0PQ) stock stays undervalued2025 Price Momentum & Weekly Stock Breakout Alerts - ulpravda.ru
Why ProQR Therapeutics N.V. stock is a value investor pick2025 Pullback Review & Risk Adjusted Swing Trade Ideas - ulpravda.ru
ProQR stock falls after initial AX-0810 data, pipeline updates By Investing.com - Investing.com Australia
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans - TipRanks
ProQR reports positive initial AX-0810 safety data in phase 1 trial - Investing.com India
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Why ProQR Therapeutics N.V. stock is considered a top pickCapital Gains Strategies & Create Passive Income With Smart Stocks - ulpravda.ru
ProQR Therapeutics N.V. (PRQR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutions - Yahoo Finance
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can ProQR Therapeutics N.V. (0PQ) stock sustain double digit ROEJuly 2025 Review & Free Technical Confirmation Trade Alerts - Улправда
Can ProQR Therapeutics N.V. stock sustain market leadershipEarnings Date Calendar & Fast Profit Trading Strategies - Bollywood Helpline
How ProQR Therapeutics N.V. (0PQ) stock gains from tech spendingWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
Can ProQR Therapeutics N.V. stock hit analyst price targetsJuly 2025 Macro Moves & Weekly Setup with ROI Potential - Улправда
Is ProQR Therapeutics N.V. stock a safe haven assetJuly 2025 Catalysts & Weekly Breakout Watchlists - Улправда
Will ProQR Therapeutics N.V. stock maintain momentum in 20252025 Key Highlights & Community Consensus Picks - Улправда
Breakout Zone: Why ProQR Therapeutics N.V. (0PQ) stock stays undervaluedWeekly Stock Summary & Low Risk High Reward Trade Ideas - Улправда
Will ProQR Therapeutics N.V. (0PQ) stock justify high valuationTrade Analysis Summary & Long-Term Growth Portfolio Plans - Улправда
Bull Run: Is ProQR Therapeutics N.V. stock a buy in volatile marketsMarket Trend Review & Real-Time Volume Analysis - Улправда
Can ProQR Therapeutics N.V. stock sustain free cash flow growthJuly 2025 Earnings & Fast Moving Trade Plans - Улправда
Is ProQR Therapeutics N.V. (0PQ) stock nearing a technical breakoutTrade Volume Report & AI Powered Trade Plan Recommendations - DonanımHaber
ProQR Therapeutics N.V PRQR’s stock price falss traction on Friday - uspostnews.com
Ready to Jump After Recent Trade: ProQR Therapeutics N.V (PRQR) - setenews.com
Is ProQR Therapeutics NV 0PQ a good long term investmentDividend Stock Watch & Free Unlock Stock Analysis - earlytimes.in
Is ProQR Therapeutics N.V. (0PQ) stock a good hedge against inflationWeekly Trade Analysis & Proven Capital Preservation Tips - Newser
Is ProQR Therapeutics N.V. (0PQ) stock a buy during volatile marketsCPI Data & Weekly Top Performers Watchlists - Newser
Will ProQR Therapeutics N.V. (0PQ) stock enhance shareholder value2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
ProQR Therapeutics N.V. (PRQR) 5.47% in After-hours: Gains Ahead of Healthcare Conference - Stocks Telegraph
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - setenews.com
Can ProQR Therapeutics N.V. (0PQ) stock surprise with quarterly results2025 Market Sentiment & Growth Focused Investment Plans - Newser
ProQR Therapeutics (PRQR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can ProQR Therapeutics N.V. (0PQ) stock ride next bull market cycleJuly 2025 Short Interest & AI Powered Buy and Sell Recommendations - Newser
How ProQR Therapeutics N.V. (0PQ) stock valuation compares with sectorQuarterly Portfolio Report & Safe Capital Growth Tips - Newser
Why ProQR Therapeutics N.V. (0PQ) stock is a strong buy callMarket Risk Report & Smart Allocation Stock Tips - Newser
How ProQR Therapeutics N.V. (0PQ) stock compares with tech leaders2025 Historical Comparison & Weekly Setup with High ROI Potential - Newser
Is ProQR Therapeutics N.V. stock attractive for hedge funds2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser
ProQR Therapeutics N.V. to Participate in 8th Annual Evercore Healthcare Conference on December 4, 2025 - Quiver Quantitative
ProQR to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewswire Inc.
How ProQR Therapeutics N.V. stock benefits from global expansionQuarterly Investment Review & Comprehensive Market Scan Reports - BỘ NỘI VỤ
Taking on analysts’ expectations and winning: ProQR Therapeutics N.V (PRQR) - setenews.com
Activity Recap: Why ProQR Therapeutics N.V. stock is a value investor pickJuly 2025 Volume & Capital Protection Trade Alerts - moha.gov.vn
ProQR Therapeutics NV Stock Analysis and ForecastVWAP Trading Strategies & Market Trend Real-Time Reports - earlytimes.in
Whale Trades: Why ProQR Therapeutics N.V. stock is considered a top pick2025 Market WrapUp & Community Consensus Picks - moha.gov.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ProQR Therapeutics N.V. (0PQ.F) analyst ratings, estimates and forecasts - Yahoo Finance Singapore
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):